In situ mass spectrometry of autoimmune liver diseases

Christopher Bowlus, Erin H. Seeley, Joanna Roder, Julia Grigorieva, Heinrich Roder, Richard M. Caprioli, M. Eric Gershwin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are the major forms of autoimmune liver diseases each characterized by the destruction of a specific liver cell type and the presence of differing auto-antibodies. We took a proteomic approach utilizing in situ matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) to obtain profiles directly from liver samples of patients with PBC, PSC, AIH and controls. The ability to precisely localize the region for acquisition of MALDI MS allowed us to obtain profiles from bile ducts, inflammatory infiltrates and hepatocytes from each biopsy sample. Analysis tools developed to identify peaks and compare peaks across diseases and cell types were used to develop models to classify the samples. Using an initial set of testing samples from PBC patients and controls, we identified unique peaks present in bile ducts, inflammatory infiltrates and hepatocytes that could classify samples in a validation cohort with 88-91% accuracy. Interestingly, profiles of PSC and AIH did not differ significantly from PBC. Identification of proteins in these peaks may represent novel autoantigens or effector molecules. These findings illustrate the potential of a proteomic approach to autoimmune diseases with in situ MALDI MS.

Original languageEnglish (US)
Pages (from-to)237-242
Number of pages6
JournalCellular and Molecular Immunology
Volume8
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Biliary Liver Cirrhosis
Autoimmune Hepatitis
Sclerosing Cholangitis
Autoimmune Diseases
Liver Diseases
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Mass Spectrometry
Bile Ducts
Proteomics
Hepatocytes
Liver
Autoantigens
Biopsy
Antibodies
Proteins

Keywords

  • autoimmune hepatitis
  • mass spectrometry
  • primary biliary cirrhosis
  • primary sclerosing cholangitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

In situ mass spectrometry of autoimmune liver diseases. / Bowlus, Christopher; Seeley, Erin H.; Roder, Joanna; Grigorieva, Julia; Roder, Heinrich; Caprioli, Richard M.; Gershwin, M. Eric.

In: Cellular and Molecular Immunology, Vol. 8, No. 3, 05.2011, p. 237-242.

Research output: Contribution to journalArticle

Bowlus, C, Seeley, EH, Roder, J, Grigorieva, J, Roder, H, Caprioli, RM & Gershwin, ME 2011, 'In situ mass spectrometry of autoimmune liver diseases', Cellular and Molecular Immunology, vol. 8, no. 3, pp. 237-242. https://doi.org/10.1038/cmi.2010.72
Bowlus C, Seeley EH, Roder J, Grigorieva J, Roder H, Caprioli RM et al. In situ mass spectrometry of autoimmune liver diseases. Cellular and Molecular Immunology. 2011 May;8(3):237-242. https://doi.org/10.1038/cmi.2010.72
Bowlus, Christopher ; Seeley, Erin H. ; Roder, Joanna ; Grigorieva, Julia ; Roder, Heinrich ; Caprioli, Richard M. ; Gershwin, M. Eric. / In situ mass spectrometry of autoimmune liver diseases. In: Cellular and Molecular Immunology. 2011 ; Vol. 8, No. 3. pp. 237-242.
@article{34f2c245589a46a48ab8091887d30cb1,
title = "In situ mass spectrometry of autoimmune liver diseases",
abstract = "Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are the major forms of autoimmune liver diseases each characterized by the destruction of a specific liver cell type and the presence of differing auto-antibodies. We took a proteomic approach utilizing in situ matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) to obtain profiles directly from liver samples of patients with PBC, PSC, AIH and controls. The ability to precisely localize the region for acquisition of MALDI MS allowed us to obtain profiles from bile ducts, inflammatory infiltrates and hepatocytes from each biopsy sample. Analysis tools developed to identify peaks and compare peaks across diseases and cell types were used to develop models to classify the samples. Using an initial set of testing samples from PBC patients and controls, we identified unique peaks present in bile ducts, inflammatory infiltrates and hepatocytes that could classify samples in a validation cohort with 88-91{\%} accuracy. Interestingly, profiles of PSC and AIH did not differ significantly from PBC. Identification of proteins in these peaks may represent novel autoantigens or effector molecules. These findings illustrate the potential of a proteomic approach to autoimmune diseases with in situ MALDI MS.",
keywords = "autoimmune hepatitis, mass spectrometry, primary biliary cirrhosis, primary sclerosing cholangitis",
author = "Christopher Bowlus and Seeley, {Erin H.} and Joanna Roder and Julia Grigorieva and Heinrich Roder and Caprioli, {Richard M.} and Gershwin, {M. Eric}",
year = "2011",
month = "5",
doi = "10.1038/cmi.2010.72",
language = "English (US)",
volume = "8",
pages = "237--242",
journal = "Cellular and Molecular Immunology",
issn = "1672-7681",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - In situ mass spectrometry of autoimmune liver diseases

AU - Bowlus, Christopher

AU - Seeley, Erin H.

AU - Roder, Joanna

AU - Grigorieva, Julia

AU - Roder, Heinrich

AU - Caprioli, Richard M.

AU - Gershwin, M. Eric

PY - 2011/5

Y1 - 2011/5

N2 - Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are the major forms of autoimmune liver diseases each characterized by the destruction of a specific liver cell type and the presence of differing auto-antibodies. We took a proteomic approach utilizing in situ matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) to obtain profiles directly from liver samples of patients with PBC, PSC, AIH and controls. The ability to precisely localize the region for acquisition of MALDI MS allowed us to obtain profiles from bile ducts, inflammatory infiltrates and hepatocytes from each biopsy sample. Analysis tools developed to identify peaks and compare peaks across diseases and cell types were used to develop models to classify the samples. Using an initial set of testing samples from PBC patients and controls, we identified unique peaks present in bile ducts, inflammatory infiltrates and hepatocytes that could classify samples in a validation cohort with 88-91% accuracy. Interestingly, profiles of PSC and AIH did not differ significantly from PBC. Identification of proteins in these peaks may represent novel autoantigens or effector molecules. These findings illustrate the potential of a proteomic approach to autoimmune diseases with in situ MALDI MS.

AB - Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are the major forms of autoimmune liver diseases each characterized by the destruction of a specific liver cell type and the presence of differing auto-antibodies. We took a proteomic approach utilizing in situ matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) to obtain profiles directly from liver samples of patients with PBC, PSC, AIH and controls. The ability to precisely localize the region for acquisition of MALDI MS allowed us to obtain profiles from bile ducts, inflammatory infiltrates and hepatocytes from each biopsy sample. Analysis tools developed to identify peaks and compare peaks across diseases and cell types were used to develop models to classify the samples. Using an initial set of testing samples from PBC patients and controls, we identified unique peaks present in bile ducts, inflammatory infiltrates and hepatocytes that could classify samples in a validation cohort with 88-91% accuracy. Interestingly, profiles of PSC and AIH did not differ significantly from PBC. Identification of proteins in these peaks may represent novel autoantigens or effector molecules. These findings illustrate the potential of a proteomic approach to autoimmune diseases with in situ MALDI MS.

KW - autoimmune hepatitis

KW - mass spectrometry

KW - primary biliary cirrhosis

KW - primary sclerosing cholangitis

UR - http://www.scopus.com/inward/record.url?scp=79955672064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955672064&partnerID=8YFLogxK

U2 - 10.1038/cmi.2010.72

DO - 10.1038/cmi.2010.72

M3 - Article

C2 - 21258365

AN - SCOPUS:79955672064

VL - 8

SP - 237

EP - 242

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

SN - 1672-7681

IS - 3

ER -